Table 1.
Summary of Galectin-1 Mutations
| Mutation | Yield (mg/l culture) | Haemagglutination. Endpoint (μg/ml) | Growth Inhibition I50 (μg/ml) |
| None | 8.0 | 1 | 5 |
| R49G* | 0.1 | 1 | nd |
| N47D* | 0.1 | 100 | nd |
| A28R* | 0.3 | - | >200 |
| D103A | 9.2 | 1 | 20 |
| P79R | 0.6 | 500 | 4 |
| C131S | 0.5 | - | 13 |
| K29M | 8.0 | 1 | - |
| K29T | 8.2 | 1 | - |
| D27N | 0.8 | 1 | 170 |
| M1R | 10.4 | 1 | - |
| M1R (thrombin) | n/a | 1 | 24 |
Yields and Biological Activities of Recombinant Galectin-1 Derivatives For each mutation in galectin-1, the yield of protein per litre of bacterial culture, the endpoint of the haemagglutination titration (in μg/ml) and the concentration giving 50% inhibition of fibroblast growth (I50, in μg/ml) are listed. The three entries marked * are for low-yield mutations, for which full analysis was not feasible. The final row contains data for the M1R mutant following thrombin cleavage and repurification.